В мартовском номере JCEM опубликованы результаты исследования, позволяющие предполагать роль определения андростендиона в диагностике биохимической гиперандрогении при СПКЯ:
Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione ([
Ссылки доступны только зарегистрированным пользователям ])
Основная мысль в изложении Brian G. Keevil (статья How Do We Measure Hyperandrogenemia in Patients With PCOS? из того же номера журнала):
Цитата:
|
It has previously been reported that androstenedione (A) can be raised when T is normal in patients with hirsutism (3) and PCOS (4), but O’Reilly et al (2) now show that patients with high A and normal T concentrations have nearly as much risk for metabolic disease as those with a high T concentration alone. The results of this study raise concern that hyperandrogenemia may be missed if only T is measured.
|